ACC 2017 was the most important congress in recent years - and a landmark for lipid lowering

The culmination of the PCSK9 revolution, the FOURIER and SPIRE-2 trials, clearly showed that lowering LDL cholesterol to very low levels, well below current goals, with a PCSK9 inhibitor reduces the risk of cardiovascular events in very high risk patients on maximal lipid lowering therapy.

These very low LDL cholesterol levels were not associated with any increase in adverse events and, in EBBINGHAUS, no detriment on neurocognition.

Join PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board as they dissect the key results from FOURIER and discuss implications for clinical practice.
	The Word from ACC 2017 - Key Results		The Word from ACC 2017 - Implications for Practice

A new era in lipid lowering is now truly here - the key question will be how we can improve access and attain the best value from PCSK9 inhibitor therapy in routine practice.
Prof Nicholls: Is FOURIER a game changer?		Prof Stein: Key messages from FOURIER		Prof Ray: Analyses FOURIER, SPIRE and ODYSSEY OUTCOMES		Prof Santos: PCSK9 inhibition cost effective?		Prof Ray: What does FOURIER mean for the FH patient?		Prof Mach: Analyses EBBINGHAUS